Nicholas Augustinos Sells 6,539 Shares of DexCom (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) Director Nicholas Augustinos sold 6,539 shares of the company’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $84.04, for a total value of $549,537.56. Following the transaction, the director directly owned 29,293 shares in the company, valued at $2,461,783.72. The trade was a 18.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nicholas Augustinos also recently made the following trade(s):

• On Monday, September 14th, Nicholas Augustinos sold 1,550 shares of DexCom stock. The stock was sold at an average price of $84.02, for a total value of $130,231.00.

DexCom Stock Up 1.0%

NASDAQ:DXCM traded up $0.89 on Wednesday, hitting $87.34. 3,541,974 shares of the company’s stock traded hands, compared to its average volume of 5,115,788. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $92.59. The firm has a 50-day moving average price of $83.25 and a 200-day moving average price of $72.98. The company has a market cap of $32.96 billion, a PE ratio of 34.52, a price-to-earnings-growth ratio of 1.42 and a beta of 1.42.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. During the same period in the prior year, the firm earned $0.48 earnings per share. The firm’s revenue was up 13.1% compared to the same quarter last year. Equities analysts anticipate that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Hedge Funds Weigh In On DexCom

Several institutional investors and hedge funds have recently added to or reduced their stakes in DXCM. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of DexCom by 15.6% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company’s stock worth $758,487,000 after purchasing an additional 1,515,702 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of DexCom by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock valued at $727,842,000 after purchasing an additional 42,411 shares in the last quarter. Norges Bank acquired a new position in shares of DexCom in the fourth quarter valued at $483,356,000. Janus Henderson Group PLC lifted its position in DexCom by 32.3% in the first quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company’s stock worth $166,077,000 after purchasing an additional 645,534 shares during the period. Finally, Legal & General Group Plc bought a new position in DexCom in the second quarter worth $173,237,000. 97.75% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on DXCM shares. Canaccord Genuity Group set a $90.00 price target on shares of DexCom and gave the company a “buy” rating in a report on Monday, August 3rd. Mizuho increased their price objective on DexCom from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Weiss Ratings raised DexCom from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Truist Financial set a $93.00 target price on DexCom and gave the stock a “buy” rating in a research report on Friday, July 31st. Finally, Wells Fargo & Company raised their price target on DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $88.71.

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.